ANAHEIM, Calif.—Prostate cancers found as a result of PSA screening are less likely to exhibit extracapsular extension and positive surgical margins after radical prostatectomy than tumors found in a non-screened population, despite similar PSA levels, data show.
For some men with localized prostate cancer, active surveillance has emerged in recent years as a viable management option.
An experimental blood test has detected prostate cancer so accurately that it could supplant PSA levels as a screening mechanism for the disease, according to researchers.
Prostate biopsies may be unwarranted in men aged 80 years and older and who have a PSA level of 30 ng/mL, according to investigators in the U.K.
Contrary to what is commonly thought, the risk of having a positive repeat prostate biopsy is no lower for men with a fluctuating PSA level than it is for those with a steady or steadily increasing PSA level.
ORLANDO—New findings presented here suggest clinicians should use a lower PSA velocity (PSAV) to recommend prostate biopsies in men who have PSA levels less than 4 ng/mL.
The most widespread nondermatologic malignancy in men, prostate cancer afflicts one in six American males and kills one in 34. Growing public awareness, an aging population, and increased PSA screening has led to greater detection of early-stage disease.
ORLANDO—A urine assay for prostate cancer gene 3 (PCA3) is superior to serum PSA tests for predicting outcomes of repeat prostate biopsy, data show.
In the PSA era, most men with newly diagnosed prostate cancer present with clinically localized disease and are curable with surgery or radiation.
ORLANDO—Intensity-modulated radiation therapy (IMRT) may offer a promising salvage option for prostate cancer patients who experience PSA relapse following radical prostatectomy, researchers said.
